右旋安非他命

右旋安非他命英語:[注 1]是强力中樞神經兴奋剂,也是苯丙胺(“安非他命”) 的对映异构体,是注意力不足過動症(ADHD)和發作性嗜睡病的处方药。[10]此外,它也被用作提升运动员能力的兴奋剂,也是一种益智药,同时人们在享乐时也将其用作春药产生欣快感的药。此外,空军也将右旋安非他命广泛用作“抗睡丸”,在诸如夜间轰炸之类的容易疲倦的任务中使用。第二次世界大战期间,该药物也被用来治疗疲倦。

右旋安非他命
INN Dexamfetamine
系统(IUPAC)命名名称
(2S)-1-phenylpropan-2-amine
临床数据
Drugs.comMonograph
MedlinePlusa605027
医疗法规
妊娠分级
  • AU: B3
  • US: C (不排除有风险的可能)
依赖性生理依赖:无
精神依赖:中
成瘾性
给药途径口服
合法狀態
合法状态
药代动力学数据
生物利用度Oral 75–100%[1]
蛋白结合度15–40%
代谢CYP2D6多巴胺β羟化酶[2] FMO3
開始出現藥效IR服用:0.5至1.5小时[3][4]
XR服用:1.5至2小时[5][6]
生物半衰期9至11小时[7]
不同的PH值:8至31小时
作用时间IR服用:3至7小时[5][8]
XR服用:12小时[5][6][8]
排泄肾(45%);[9]取决于尿液的pH值
识别
CAS注册号51-64-9  
ATC代码N06BA02
PubChemCID 5826
IUPHAR/BPS2147
DrugBankDB01576 
ChemSpider5621 
UNIITZ47U051FI 
KEGGD03740 
ChEBICHEBI:4469 
ChEMBLCHEMBL612 
化学
化学式C9H13N
摩尔质量135.20622
物理性质
密度0.913 g/cm3
沸点201.5 °C(394.7 °F)
水溶液20 mg/mL (20 °C)

脚注

  1. 其他英文名称:dexamphetamineAAN)、dexamfetamine国际非专利药品名称BAN)、(S)-amphetamine(+)-amphetamineD-amphetamine

参考资料

  1. . . DrugBank. [2013-11-05]. (原始内容存档于2019-08-06).
  2. Lemke TL, Williams DA, Roche VF, Zito W. 7th. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2013: 648. ISBN 1609133455. Alternatively, direct oxidation of amphetamine by DA β-hydroxylase can afford norephedrine.
  3. Green-Hernandez, Carol; Singleton, Joanne K.; Aronzon, Daniel Z. . Lippincott Williams & Wilkins. 2001-01-01: 243 [2017-05-07]. ISBN 9780781720083. (原始内容存档于2016-05-23).|quote = Table 21.2 Medications for ADHD ... D-amphetamine ... Onset: 30 min.
  4. . reference.medscape.com. [2015-10-04]. (原始内容存档于2018-11-06). Onset of action: 1–1.5 hr
  5. Millichap JG. . Millichap JG (编). 2nd. New York, USA: Springer. 2010: 112. ISBN 9781441913968.
    Table 9.2 Dextroamphetamine formulations of stimulant medication
    Dexedrine [Peak:2–3 h] [Duration:5–6 h] ...
    Adderall [Peak:2–3 h] [Duration:5–7 h]
    Dexedrine spansules [Peak:7–8 h] [Duration:12 h] ...
    Adderall XR [Peak:7–8 h] [Duration:12 h]
    Vyvanse [Peak:3–4 h] [Duration:12 h]
  6. Brams M, Mao AR, Doyle RL. . Postgrad. Med. September 2008, 120 (3): 69–88. PMID 18824827. doi:10.3810/pgm.2008.09.1909. Onset of efficacy was earliest for d-MPH-ER at 0.5 hours, followed by d, l-MPH-LA at 1 to 2 hours, MCD at 1.5 hours, d, l-MPH-OR at 1 to 2 hours, MAS-XR at 1.5 to 2 hours, MTS at 2 hours, and LDX at approximately 2 hours. ... MAS-XR, and LDX have a long duration of action at 12 hours postdose
  7. (PDF). United States Food and Drug Administration. Teva Pharmaceuticals USA, Inc.: 1–6. October 2015 [2016-05-18]. (原始内容存档 (PDF)于2018-09-15).
  8. Mignot EJ. . Neurotherapeutics. October 2012, 9 (4): 739–752. PMC 3480574. PMID 23065655. doi:10.1007/s13311-012-0150-9.
  9. . DailyMed. Wayne, PA: Shire US Inc. August 2006 [2013-11-08]. (原始内容存档于2012-01-13).
  10. (PDF). United States Food and Drug Administration. Amedra Pharmaceuticals LLC: 1–7. February 2015 [2015-09-04]. (原始内容存档 (PDF)于2017-02-17).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.